NVS Novartis AG

86.59
+0.31  (+0%)
Previous Close 86.28
Open 86.47
Price To Book 3.86
Market Cap 198,444,488,037
Shares 2,291,771,429
Volume 206,269
Short Ratio 2.26
Av. Daily Volume 2,067,052

NewsSee all news

  1. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Novartis AG

    NEW YORK, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Novartis AG ("Novartis" or "the Company") (NYSE:NVS) concerning possible violations of

  2. ROSEN, A LEADING LAW FIRM, Continues To Investigate Securities Claims Against Novartis AG – NVS

    Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE:NVS) resulting from allegations that Novartis may have issued

  3. ROSEN, A TOP RANKED LAW FIRM, Continues To Investigate Securities Claims Against Novartis AG – NVS

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE:NVS) resulting from

  4. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Novartis AG

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Novartis AG ("Novartis" or "the Company") (NYSE:NVS) concerning possible violations of

  5. EQUITY ALERT: Rosen Law Firm Continues To Investigate Securities Claims Against Novartis AG – NVS

    NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE:NVS) resulting from

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Head-to-head trial versus proposed biosimilar adalimumab initiated. Expected completion 2022.
Cosentyx (secukinumab) - SURPASS
Ankylosing spondylitis (AS)
Approval announced April 30, 2018.
Tafinlar (dabrafenib) and Mekinist (trametinib)
Melanoma with BRAF V600E or V600K mutations
Phase 3 trial to be completed 1H 2020.
Lu-PSMA-617 VISION
Metastatic castration-resistant prostate cancer (mCRPC)
Approval announced May 11, 2018.
Fingolimod
Multiple Sclerosis (MS)
Phase 1 data at AAN May 5, 2019 noted motor function gains.
Zolgensma AVXS-101 STRONG
Spinal muscular atrophy (SMA) Type 2
FDA Approval announced June 22, 2017.
Tafinlar (dabrafenib) and Mekinist (trametinib)
Non-small cell lung cancer (NSCLC) with BRAF V600E mutation
Approval announced May 1, 2018.
Kymriah (CTL019 )- JULIET
Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 3 updated data at ASCO June 4, 2017.
Ribociclib + Letrozole - MONALEESA-2
Breast cancer
CRL issued May 2, 2018.
Biosimilar rituximab
Various blood cancers, rheumatoid arthritis.
Priority review granted February 22, 2017. Approval announced May 26, 2017.
Zykadia
First-line use in patients with ALK+ metastatic NSCLC
Phase 3 data due 2H 2019.
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3 data due 2H 2019.
Ruxolitinib - REACH 2
Steroid-refractory acute GVHD (Graft versus host disease)
CRL announced October 18, 2018.
ACZ885 (canakinumab)
CV risk reduction
Phase 3 data released March 22, 2017 - primary endpoints not met.
RELAX-AHF-2 (RLX030)
Acute heart failure
PDUFA date under priority review estimated October 15, 2019 using six-month timeline. Exact date not provided by company.
RTH258 (brolucizumab)
Neovascular AMD
Phase 3 trial to be completed 3Q 2019.
QVM149
Asthma
Phase 3 data due 1Q 2020.
QAW039 (fevipiprant) - LUSTER-1
Asthma
Phase 3 trial met primary endpoint - November 8, 2017.
LEE011: MONALEESA-7
Breast cancer - (pre-menopausal)
Phase 3 data met endpoints - August 30, 2019. Data presented at ECTRIMS September 13, 2019 noted reduction in annualized relapse rate (ARR) by 50.5% and 58.8% compared to Aubagio.
OMB157 (ofatumumab)
Relapsing multiple sclerosis
Phase 3 data presented at ASCO 2018 - PFS 20.5 months v 12.8 months. Overall survival secondary endpoint met - July 31, 2019. Presentation at ESMO September 29, 2019; 4:45pm.
Kisqali plus fulvestrant: MONALEESA-3
Breast cancer - (post-menopausal)
Phase 3 trial did not meet primary endpoint - July 29, 2019.
Entresto - PARAGON-HF
HF-pEF (heart failure with preserved ejection fraction)
Phase 3 trial completion due 2H 2020.
Entresto - PARADISE
AMI (acute myocardial infarction)
Approval announced early - August 30, 2017.
Kymriah (CTL019)
Relapsed/Refractory B-Cell Acute lymphoblastic leukemia
Approval announced May 17, 2018.
Erenumab
Migraine
Phase 3 ongoing. Expected completion 2024.
CNP 520
Alzheimer’s Disease
Priority review granted November 14, 2016. Approval announced April 28, 2017.
Rydapt (Midostaurin - PKC412)
Acute myeloid leukemia (AML)
Priority review granted November 1, 2016. Approval announced March 13, 2017.
LEE011
HR+/HER2- advanced breast cancer
FDA approval announced October 31, 2018.
Adalimumab
Rheumatoid Arthritis
Approved January 26, 2018. Acquired from Advanced Accelerator Applications (NASDAQ: AAAP).
Lutathera
Inoperable progressive midgut NETs
FDA Approval announced May 24, 2019.
Zolgensma AVXS-101
Spinal muscular atrophy (SMA) Type 1
Phase 3 data May 5, 2019 noted 11/22 patients who could sit without support for at least 30 seconds. To be completed in 2021.
Zolgensma AVXS-101 STR1VE EU
Spinal muscular atrophy (SMA) Type 1
Phase 2 trial to be completed 1H 2020.
LJN452
Non-alcoholic steatohepatitis (NASH)
NDA filing due 2019.
INC280
Non-small cell lung cancer
Program discontinued - noted July 18, 2018.
LIK066
Obesity
FDA Approval announced May 24, 2019.
BYL719 + fulvestrant
HR + Metastatic breast cancer (MBC)
FDA approval announced February 8, 2018.
Cosentyx
Psoriasis
Phase 3 data May 5, 2019 noted all patients (18/18) were alive and event-free. Completion 2021.
Zolgensma AVXS-101 SPRINT
Pre-symptomatic patients with spinal muscular atrophy (SMA) Types 1, 2 and 3
sNDA approval announced November 16, 2018.
Promacta (eltrombopag)
Severe aplastic anemia (SAA)
FDA approval announced March 26, 2019.
Mayzent (siponimod/BAF312)
Secondary progressive multiple sclerosis
Phase 3 data due 4Q 2019.
PDR001
BRAFV600 mutant metastatic melanoma
Phase 3 data noted 46% reduction in serious clinical outcomes endpoint.
Entresto - PIONEER
Heart failure
PDUFA date under priority review announced July 16, 2019. Estimate PDUFA date based on 6-month review is January 15, 2020.
Crizanlizumab
Sickle cell disease
Phase 3 trial completed 1Q 2019.
Entresto - PARALLEL-HF
Heart failure
Phase 3 trial met primary endpoint - September 17, 2019.
Cosentyx (secukinumab) - PREVENT
Non-radiographic axial spondyloarthritis
FDA Approval announced February 13, 2019.
Egaten
Fascioliasis
BLA filing resubmission announced April 3, 2019 in response to CRL issued in 2017. Estimated PDUFA date February 3, 2020.
Biosimilar pegfilgrastim
Pegfilgrastim biosimilar
Phase 3 trial to be completed 2022.
Entresto - PERSPECTIVE
Heart failure
Phase 3 trial to be completed 2021.
Entresto - Panorama
Heart failure
Phase 3 trial met primary endpoint.
QMF149
Asthma
Phase 3 trials met primary endpoints - June 3, 2019.
Xolair (omalizumab)
Chronic rhinosinusitis with nasal polyps (CRSwNP)
Phase 2/3 trial discontinued due to lack of efficacy.
CNP520
Alzheimer’s Disease
Phase 3 data due 4Q 2019.
QAW039 (fevipiprant) - ZEAL
Asthma

Latest News

  1. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Novartis AG

    NEW YORK, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Novartis AG ("Novartis" or "the Company") (NYSE:NVS) concerning possible violations of

  2. ROSEN, A LEADING LAW FIRM, Continues To Investigate Securities Claims Against Novartis AG – NVS

    Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE:NVS) resulting from allegations that Novartis may have issued

  3. ROSEN, A TOP RANKED LAW FIRM, Continues To Investigate Securities Claims Against Novartis AG – NVS

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE:NVS) resulting from

  4. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Novartis AG

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Novartis AG ("Novartis" or "the Company") (NYSE:NVS) concerning possible violations of

  5. EQUITY ALERT: Rosen Law Firm Continues To Investigate Securities Claims Against Novartis AG – NVS

    NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE:NVS) resulting from